Leptin/adiponectin ratio correlates with hepatic steatosis but not arterial stiffness in nonalcoholic fatty liver disease in Japanese population

Mikami, Koji; Endo, Tetsu; Sawada, Naoya; Igarashi, Go; Kimura, Masayo; Hasegawa, Takuma; Iino, Chikara; Tomita, Hirofumi; Sawada, Kaori; Nakaji, Shigeyuki; Matsuzaka, Masashi; Török, Natalie J.; Fukuda, Shinsaku

doi:10.1016/j.cyto.2019.154927

Cited by 17 publications

(8 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was reported that adiponectin to leptin ratio, being known as a marker of dysfunctional adipose tissue, was significantly reduced in metabolic syndrome patients [ 45 ]. Furthermore, the leptin to adiponectin ratio and arterial stiffness were found to correlate with hepatic steatosis severity [ 46 ]. However, no significant association was reported between leptin to adiponectin ratio and arterial stiffness in NAFLD, suggesting that other pathogenic links might be related to atherosclerosis in NAFLD.…”

Section: Discussionmentioning

confidence: 99%

Metabolic biomarkers related to cardiac dysfunction in metabolic-dysfunction-associated fatty liver disease: a cross-sectional analysis

et al. 2022

View full text Add to dashboard Cite

Introduction Hepatic steatosis is associated with cardiac systolic and diastolic dysfunction. Therefore, we evaluated metabolites and their potential cardiovascular effects in metabolic-dysfunction-associated fatty liver disease (MAFLD). Materials and methods We conducted a cross-sectional study involving 75 participants (38 MAFLD and 37 controls). Hepatic steatosis was confirmed by hepatic ultrasonography and SteatoTestTM. Cardiac function was assessed using echocardiography. Metabolomic analysis was conducted using ultra-high-performance liquid chromatography–mass spectrometry. Results The median age for participants’ age was 45 (IQR 30–56.5), with gender distribution of 35 males and 40 females. MAFLD patients had lower levels of glycyl tyrosine (p-value < 0.001), lysophosphatidylcholine (LPC) (18:2/0:0) (p-value < 0.001), LPC (22:6) (p-value < 0.001), and ceramide (Cer) (d18:0/23:0) (p-value 0.003) compared to controls. MAFLD patients presented lower left ventricular ejection fraction (LVEF), E/A ratio, E/e′ ratio, and average global longitudinal strain (GLS) values, with a p-value of 0.047, <0.001, 0.008, and <0.001, respectively. Decreased glycyl tyrosine levels were significantly correlated with reduced LVEF, even after performing multiple linear regression with 95% CI (1.34–3.394, p-value < 0.001). Moreover, decreased LPC (18:2/0:0) levels remained significantly associated with E/A ratio, even after adjusting for confounding factors with 95% CI (0.008–0.258, p-value = 0.042). Conclusion MAFLD patients are at risk for developing cardiac systolic and subclinical systolic dysfunctions, as well as diastolic dysfunction. Decreased glycyl tyrosine levels correlate with reduced LVEF and LPC (18:2/0:0) levels with diastolic dysfunction, even after adjusting for confounding factors, suggesting their potential to be used as metabolic biomarkers in detecting cardiovascular risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Metabolic biomarkers related to cardiac dysfunction in metabolic-dysfunction-associated fatty liver disease: a cross-sectional analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…To date, we have shown the association of NAFLD with adipokines, microbiota, and changed amino acids in this health promotion study. (20)(21)(22) Our research on the association of NAFLD with skeletal muscle mass and strength is one part of this project. In 2016, 1,148 individuals were enrolled in this project.…”

Section: Methodsmentioning

confidence: 99%

Association of serum creatinine-to-cystatin C ratio with skeletal muscle mass and strength in nonalcoholic fatty liver disease in the Iwaki Health Promotion Project

Mikami

Endo

Sawada

et al. 2022

J. Clin. Biochem. Nutr.

Self Cite

View full text Add to dashboard Cite

We evaluated the feasibility of using serum creatinine-to-cystatin C ratio in the assessments of muscle mass and strength in nonalcoholic fatty liver disease. In a community-based crosssectional study, skeletal muscle mass and handgrip strength were assessed in 641 Japanese adults. Low skeletal muscle mass index and low handgrip strength were defined as indicated in the sarcopenia diagnostic criteria of the Japan Society of Hepatology. Nonalcoholic fatty liver disease was defined as fatty liver on ultrasonography in the absence of other causes of steatosis. The creatinine-to-cystatin C ratio was useful for identifying the participants with low skeletal muscle mass index, with an area under the receiver-operating characteristic curve of 0.84 [95% confidence interval (CI), 0.77-0.91] in men and 0.72 in women (95% CI, 0.65-0.78), and those with low handgrip strength, with an area under the receiver-operating characteristic curve of 0.96 (95% CI, 0.93-0.99) in men and 0.79 (95% CI, 0.66-0.92) in women. Moreover, the creatinine-to-cystatin C ratio correlated with skeletal muscle mass index (r = 0.511, p<0.001) and handgrip strength (r = 0.657, p<0.001), whereas it did not correlate with exacerbation of hepatic steatosis. In this study, creatinine-tocystatin C ratio correlated with muscle mass and strength in nonalcoholic fatty liver disease regardless of hepatic steatosis.

show abstract

“…Increased levels of leptin were found in subjects with increased body fat and cardiometabolic disorders [ 92 ]. Authors noted in a cross-sectional study that NAFLD patients have lower adiponectin levels, higher serum leptin levels, and higher leptin-to-adiponectin (L/A) ratio [ 93 ]. Adiponectin and leptin can independently predict the onset of NAFLD that is why they may be taken into consideration as potential predictive biomarkers for NAFLD [ 94 ].…”

Section: Immunopathogenesismentioning

confidence: 99%

The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD)

Tănase

Gosav

Costea

et al. 2020

Journal of Diabetes Research

281

180

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) remain as one of the most global problematic metabolic diseases with rapidly increasing prevalence and incidence. Epidemiological studies noted that T2DM patients have by two-fold increase to develop NAFLD, and vice versa. This complex and intricate association is supported and mediated by insulin resistance (IR). In this review, we discuss the NAFLD immunopathogenesis, connection with IR and T2DM, the role of screening and noninvasive tools, and mostly the impact of the current antidiabetic drugs on steatosis liver and new potential therapeutic targets.

show abstract

Leptin/adiponectin ratio correlates with hepatic steatosis but not arterial stiffness in nonalcoholic fatty liver disease in Japanese population

Cited by 17 publications

References 77 publications

Metabolic biomarkers related to cardiac dysfunction in metabolic-dysfunction-associated fatty liver disease: a cross-sectional analysis

Metabolic biomarkers related to cardiac dysfunction in metabolic-dysfunction-associated fatty liver disease: a cross-sectional analysis

Association of serum creatinine-to-cystatin C ratio with skeletal muscle mass and strength in nonalcoholic fatty liver disease in the Iwaki Health Promotion Project

The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD)

Contact Info

Product

Resources

About